$ANL News

Oppenheimer Initiates Coverage On Adlai Nortye with Outperform Rating, Announces Price Target of $32

Jones Trading Initiates Coverage On Adlai Nortye with Buy Rating, Announces Price Target of $22

Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?

Here's Why Adlai Nortye Ltd. Sponsored ADR (ANL) Is a Great 'Buy the Bottom' Stock Now

H.C. Wainwright Sees “Potential Best-in-Class Potency” for Adlai Nortye’s (ANL) Lead Asset, Lifts PT

Adlai Nortye: Recapitalized, Refocused, But Still Too Early To Upgrade

Adlai Nortye (ANL): 10 Tiny Stocks That Are On Fire Right Now

Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?

HC Wainwright & Co. Maintains Buy on Adlai Nortye, Raises Price Target to $20

Adlai Nortye Announces $150.0 Million Private Placement Equity Financing

Adlai Nortye shares are trading higher after the company announced it has entered into a $150 million securities purchase agreement for a private investment in public equity financing.

Adlai Nortye shares are trading higher after the company announced it has entered into a $150 million securities purchase agreement for a private investment in public equity financing.

Adlai Nortye Enters Into Securities Purchase Agreement For Private Investment In Public Equity Financing That Is Expected To Result In Gross Proceeds Of ~$150M

Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?

Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's Why

HC Wainwright & Co. Upgrades Adlai Nortye to Buy, Announces $16 Price Target

Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations

Adlai Nortye Dosed The First Patient In US In Early February In Its Ongoing Phase 1 Trial Of AN9025 For Solid Tumors Harboring RAS Mutations

Is the Market Bullish or Bearish on Adlai Nortye Ltd?

Adlai Nortye shares are trading higher after the company announced a $140 million private placement equity financing.